The Cancer Money Trail: From Patent to Patient

The patent is not the finish line. It can be the point at which a research discovery enters a much more demanding and expensive process: development in people, regulatory review, manufacturing, and eventually use in clinical practice.

Part 5 followed the trail from research to patents and licensing. Part 6 follows what comes next — the attempt to turn a promising discovery into a medicine that can actually be given to patients.

From a laboratory result to a human treatment

The U.S. Food and Drug Administration describes drug development as a sequence that begins with discovery and development, moves through preclinical research and clinical research, then reaches FDA review and post-market safety monitoring.

That sequence matters because an interesting laboratory result is not the same thing as a proven treatment. Before a new drug can be tested in people, developers generally need evidence from laboratory and animal studies supporting a reasonable basis for human testing.

Thousands of potential compounds can be considered during discovery. Only a small number continue far enough to become serious development candidates. That attrition is one reason the existence of a patent should never be treated as evidence that a medicine will reach patients.

The clinical-trial gateway

Once a developer is ready to study a drug in people, it generally submits an Investigational New Drug application to the FDA. The submission includes information such as preclinical data, manufacturing information and the proposed clinical protocols.

Human research then proceeds through phases designed to answer different questions. Phase 1 primarily examines safety, tolerability and dosing. Phase 2 provides additional safety information and investigates whether the treatment appears to work against the target disease. Phase 3 uses larger groups to establish whether the treatment provides a meaningful benefit and to identify less common adverse effects.

NCI explains that cancer trials have a particular feature: early trials of a new cancer treatment are generally conducted in people with cancer rather than healthy volunteers because the treatment may carry substantial risks.

What the numbers tell us about attrition

FDA's current clinical-research guidance says approximately 70% of drugs move from Phase 1 to Phase 2, about 33% move from Phase 2 to Phase 3, and roughly 25%–30% move from Phase 3 toward the next stage. These are broad development-stage figures, not a guarantee for any individual cancer drug.

The lesson for the money trail is straightforward: money spent on research does not create a straight line to approval. At every stage, scientific results can stop a programme.

Who pays for the later stages?

The funding structure can change as a project advances. Early work may be supported by government agencies, universities, charities or other research organisations. A company may later take responsibility for development, including clinical trials, manufacturing and preparation of a marketing application.

That means the funding history of a medicine can contain multiple layers rather than one source of money. A public grant supporting an early discovery does not tell us how much a later company spent, and a company's later investment does not erase the contribution of earlier public or charitable research.

For an individual case, the correct question is therefore not simply “Who paid for the drug?” It is: who paid for which stage, under which agreement, and with what rights or obligations?

FDA approval is another evidence checkpoint

For a conventional New Drug Application, the developer submits the evidence gathered during preclinical and clinical development. FDA reviewers examine the data and assess whether the evidence supports safety and effectiveness for the proposed use, whether the benefits outweigh the known risks, and whether manufacturing controls are adequate.

FDA review is not the same as FDA-funded development. The agency does not develop new therapies or conduct the sponsor's clinical trials. Its role is regulatory review and oversight.

An approval therefore means that the FDA has determined, under the applicable legal and scientific standard, that the drug's benefits outweigh its known and potential risks for the intended population and use. It does not mean the drug is risk-free, universally effective, or guaranteed to work for every patient.

Approval does not end the evidence trail

FDA's process continues after approval. Post-market safety monitoring can identify adverse events and other information that was not visible during the pre-approval studies.

This matters because clinical trials have finite sizes and durations. Rare or long-term effects may only become apparent when a treatment is used by many more people over a longer period.

And approval does not set the price

One of the most important distinctions in the cancer money trail is that FDA approval and drug pricing are separate questions.

FDA states that it does not control the cost of drugs or determine the financial terms between patients, providers, insurers and manufacturers. The price and the amount ultimately paid can involve manufacturers, wholesalers, pharmacies, insurers, employers, government programmes and patients.

So a complete investigation of a cancer medicine cannot stop at “FDA approved.” It eventually has to ask what happened to the medicine's price, coverage and access after approval.

A real example: Taxol shows why the trail is complicated

Part 5 examined Taxol, based on paclitaxel, as a documented example involving NCI research, university technology, Bristol-Myers Squibb and clinical development.

Taxol also demonstrates why tracing a medicine requires more than identifying its original discovery. The development pathway included laboratory research, clinical trials, manufacturing challenges, technology licensing and regulatory approval at different points.

The record therefore contains multiple contributors and stages. It would be misleading to attribute the final medicine's entire scientific or financial history to a single institution simply because that institution played an important early role.

What can we actually measure?

For a specific cancer medicine, a serious money-trail investigation can try to establish:

• the original research funder and award;
• the recipient institution and investigators;
• the invention disclosure and patent record, where available;
• licensing arrangements and identified technology-transfer partners;
• the company or companies responsible for later development;
• clinical-trial sponsors and registered trials;
• FDA approval and the approved indication;
• later safety or regulatory actions;
• and, where reliable public records permit, pricing, reimbursement and commercial information.

Each item answers a different question. They should not be collapsed into one figure unless the underlying evidence supports that calculation.

The key distinction: contribution is not ownership

A government agency may fund research without owning every resulting commercial right. A university may own or license an invention without paying all development costs. A company may finance clinical trials without having originated the underlying discovery.

The final product can therefore be the result of a chain of contributions. Following that chain is more informative than asking which sector “invented” the medicine.

Where the money trail goes next

Parts 1–6 have now moved from the disease itself, through global research funding, geographic concentration, recipients, intellectual property and the development pathway.

The next question is increasingly financial: once an approved cancer medicine reaches the market, where does the money go?

That means looking at pricing, insurers and government programmes, rebates and discounts where records permit, manufacturer revenue, and the difference between the list price and what different buyers actually pay.

That is where the investigation moves from the cost of discovering a treatment to the economics of paying for it.

← Read Part 5: From Research to Patents and Licensing

Next: Part 7 — Following the Price

Sources

• FDA — The Drug Development Process
• FDA — Step 3: Clinical Research
• FDA — Step 4: FDA Drug Review
• FDA — How Drugs Are Developed and Approved
• FDA — Drug Review Process: Ensuring Drugs Are Safe and Effective
• FDA — Role in Drug Approval and Costs
• NCI — How Do Clinical Trials Work?
• NCI — Clinical Trials Programs and Initiatives
• NCI — Taxol: An NIH Success Story
• NIH — Commercializing Inventions